AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AstraZeneca PLC Director's Dealing 2012

Oct 12, 2012

5229_dirs_2012-10-12_fc4b9873-59dd-47de-ba4c-37a4cf5bb014.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Regulus Therapeutics Inc. (RGLS)
CIK: 0001505512
Period of Report: 2012-10-10

Reporting Person: ASTRAZENECA PLC (10% Owner)
Reporting Person: ASTRAZENECA AB (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
COMMON STOCK	6250000	Indirect

Footnotes

F1: The securities are owned directly by AstraZeneca AB, a wholly-owned, indirect subsidiary of AstraZeneca PLC. AstraZeneca is an indirect beneficial owner of the reported securities.